drugset
drugset / Trial / NCT04514835

A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC

NCT04514835 ↗

Phase 2 Unknown 44 enrolled The First Affiliated Hospital of Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of Sintilimab for Consolidation Therapy After Radical Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Timeline

Start
2021-12-01
Primary completion
2022-01-31
Completion
2023-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg —
Background Capecitabine Small molecule 800 mg/m2 —
Background Cisplatin Other / unclassified 25 mg/m2 Intravenous
Background Cisplatin Other / unclassified 30 mg/m2 Intravenous

Indications

esophageal squamous cell carcinoma